Abstract
G protein coupled receptors (GPCRs) are the most historically successful therapeutic targets. Despite this success there are many important aspects of GPCR pharmacology and function that have yet to be exploited to their full therapeutic potential. One in particular that has been gaining attention in recent times is that of GPCR ligands that bind to allosteric sites on the receptor distinct from the orthosteric site of the endogenous ligand. As therapeutics, allosteric ligands possess many theoretical advantages over their orthosteric counterparts, including more complex modes of action, improved safety, more physiologically appropriate responses, better target selectivity, and reduced likelihood of desensitisation and tachyphylaxis. Despite these advantages, the development of allosteric ligands is often difficult from a medicinal chemistry standpoint due to the more complex challenge of identifying allosteric leads and their often flat or confusing SAR. The present review will consider the advantages and challenges associated with allosteric GPCR ligands, and examine how the particular properties of these ligands may be exploited to uncover the therapeutic potential for free fatty acid sensitive GPCRs.
Keywords: Allosteric ligand, FFA1-3, free fatty acid, GPCR, GPR84, GPR120 orthosteric ligand
Current Topics in Medicinal Chemistry
Title:The Therapeutic Potential of Allosteric Ligands for Free Fatty Acid Sensitive GPCRs
Volume: 13 Issue: 1
Author(s): Brian D. Hudson, Trond Ulven and Graeme Milligan
Affiliation:
Keywords: Allosteric ligand, FFA1-3, free fatty acid, GPCR, GPR84, GPR120 orthosteric ligand
Abstract: G protein coupled receptors (GPCRs) are the most historically successful therapeutic targets. Despite this success there are many important aspects of GPCR pharmacology and function that have yet to be exploited to their full therapeutic potential. One in particular that has been gaining attention in recent times is that of GPCR ligands that bind to allosteric sites on the receptor distinct from the orthosteric site of the endogenous ligand. As therapeutics, allosteric ligands possess many theoretical advantages over their orthosteric counterparts, including more complex modes of action, improved safety, more physiologically appropriate responses, better target selectivity, and reduced likelihood of desensitisation and tachyphylaxis. Despite these advantages, the development of allosteric ligands is often difficult from a medicinal chemistry standpoint due to the more complex challenge of identifying allosteric leads and their often flat or confusing SAR. The present review will consider the advantages and challenges associated with allosteric GPCR ligands, and examine how the particular properties of these ligands may be exploited to uncover the therapeutic potential for free fatty acid sensitive GPCRs.
Export Options
About this article
Cite this article as:
D. Hudson Brian, Ulven Trond and Milligan Graeme, The Therapeutic Potential of Allosteric Ligands for Free Fatty Acid Sensitive GPCRs, Current Topics in Medicinal Chemistry 2013; 13 (1) . https://dx.doi.org/10.2174/1568026611313010004
DOI https://dx.doi.org/10.2174/1568026611313010004 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Bisphosphonates and Calcium plus Vitamin-D Supplements on Cognitive Function in Postmenopausal Osteoporosis§
Endocrine, Metabolic & Immune Disorders - Drug Targets Insight to the Pathophysiology of Stable Angina Pectoris
Current Pharmaceutical Design Increased Salt Sensitivity in Obese Hypertension: Role of the Sympathetic Nervous System
Current Hypertension Reviews Socio-economic Aspects of Alzheimer's Disease
Current Alzheimer Research Exogenous Hormonal Regulation in Breast Cancer Cells by Phytoestrogens and Endocrine Disruptors
Current Medicinal Chemistry Tumor-Intrinsic and Tumor-Extrinsic Factors Impacting Hsp90- Targeted Therapy
Current Molecular Medicine Mitochondrial Deficits Accompany Cognitive Decline Following Single Bilateral Intracerebroventricular Streptozotocin
Current Alzheimer Research ALA, Fatty Fish or Marine n-3 Fatty Acids for Preventing DM?: A Systematic Review and Meta-Analysis
Current Diabetes Reviews Glycogen Phosphorylase as a Target for Type 2 Diabetes: Synthetic, Biochemical, Structural and Computational Evaluation of Novel N-acyl-N´-(<i>β</i>-D-glucopyranosyl) Urea Inhibitors
Current Topics in Medicinal Chemistry An Association of Virus Infection with Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Frontier View on Nanotechnological Strategies for Neuro-therapy
Current Drug Metabolism Developments in Growth Hormone Delivery
Current Drug Therapy Thrombocytopenia in HIV Infection: Impairment of Platelet Formation and Loss Correlates with Increased c-Mpl and Ligand Thrombopoietin Expression
Current HIV Research Effects of Diabetic HDL on Endothelial Cell Function
Cardiovascular & Hematological Disorders-Drug Targets Mitochondrial MMP Activation, Dysfunction and Arrhythmogenesis in Hyperhomocysteinemia
Current Vascular Pharmacology From Structure – Based to Knowledge – Based Drug Design Through X-Ray Protein Crystallography: Sketching Glycogen Phosphorylase Binding Sites
Current Medicinal Chemistry Advanced Glycation End Products (AGEs) and their Involvement in Liver Disease
Current Pharmaceutical Design Regulation of Iron Absorption in Hemoglobinopathies
Current Molecular Medicine Intrauterine Effects of Impaired Lipid Homeostasis in Pregnancy Diseases
Current Medicinal Chemistry Advances in Current Diabetes Proteomics: From the Perspectives of Label- free Quantification and Biomarker Selection
Current Drug Targets